Yan Leyfman: Gene-Editing Strategies for CAR T Cell Therapies
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article on LinkedIn:
“This research evaluates gene-editing strategies for CAR T cell therapies. Findings indicate that CRISPR/Cas9 nucleases may reduce CAR T cell fitness due to genotoxic stress and DNA damage responses.
In contrast, adenine base editors (ABEs) showed improved outcomes:
- Higher editing precision and manufacturing yield.
- Enhanced proliferation under antigen stress.
- Lower activation of DNA damage and p53 pathways.
- Improved antitumor efficacy in preclinical models.
These results support the potential of ABE-based editing for developing next-generation allogeneic CAR T cell therapies.”
Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells.
Authors: Nils W. Engel, Israel Steinfeld, Daniel Ryan, Kusala Anupindi, Samuel Kim, Nils Wellhausen, Linhui Chen, Katherine Wilkins, Daniel J. Baker, Philipp C. Rommel, Danuta Jarocha, Mercy Gohil, Qian Zhang, Michael C. Milone, Joseph A. Fraietta, Megan Davis, Regina M. Young, and Carl H. June.
You can read the Full Article on Journal of PNAS.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023